Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI versus VI for bone mineral density in COPD
NL-OMON44651Phase 4Active, not recruiting
- Sponsor
- GSK
- Start
- Feb 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Fluticasone furoate + vilanterol with Vilanterol (2 arms). Primary endpoint: Hip bone mineral density. Started Feb 2014; status: active, not recruiting.
02
Drugs
fluticasonevilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON44651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44651.